Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PD-1 knockout engineered T cells - Anhui Kedgene Biotechnology

Next Previous
X
Search
Drug Profile

PD-1 knockout engineered T cells - Anhui Kedgene Biotechnology

Latest Information Update: 17 Sep 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anhui Kedgene Biotechnology
  • Developer Anhui Kedgene Biotechnology; Hangzhou Cancer Hospital
  • Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Oesophageal cancer

Most Recent Events

  • 01 Dec 2020 No development reported - Phase-II for Oesophageal cancer (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (IV)
  • 13 Jun 2018 Interim efficacy and adverse events data from a Phase-II trial in Advanced Esophageal Cancer presented at The 54th Annual Meeting of the American Society of Clinical Oncology(ASCO-2018)
  • 20 Mar 2017 Phase-II clinical trials in Oesophageal cancer (Metastatic disease, Second-line therapy or greater, Recurrent, Late-stage disease) in China (IV, Infusion) (NCT03081715)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top